Cargando…
The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since these drugs not only improve glycemia with minimal risk of hypoglycemia, but also have other extraglycemic beneficial effects. These agents, which are effective in improving glucose control, could als...
Autores principales: | Pala, L., Rotella, C. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703341/ https://www.ncbi.nlm.nih.gov/pubmed/23853775 http://dx.doi.org/10.1155/2013/590456 |
Ejemplares similares
-
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011) -
DPP4 as a Potential Candidate in Cardiovascular Disease
por: Chen, Si-Yu, et al.
Publicado: (2022) -
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021) -
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012) -
The regulatory role of DPP4 in atherosclerotic disease
por: Duan, Lihua, et al.
Publicado: (2017)